BioMedNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Launches ‘Gold Standard’ of Mass Spectrometry into Narcotics Detection Market

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the company is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (“NTD”). A high-performance laboratory instrument, the TRACER 1000 NTD is capable of rapid detection of trace levels of narcotic compounds in seconds. With the company’s Tracer 1000 Explosive Trace Detector (“ETD”) now found in multiple locations in 14 countries, the NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement. “Over the last five years our ETD instruments have proven their durability, reliability, and their specificity with a false alarm rate of less than 2% in actual airport and cargo environments. We are very excited about introducing our narcotics detection library that includes twelve illegal drugs including fentanyl, heroin and cocaine,” said Thomas B. Pickens, III, Astrotech’s chairman, CEO and CTO. “And we look forward to providing the same level of quality instrumentation to the narcotic trace detector customer.”

To view the full press release, visit https://ibn.fm/e2kZf

About Astrotech Corporation

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures and sells trace detectors for use in the security and detection market. Astrotech is headquartered in Austin, Texas. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN